production, Author at Juvena Therapeutics

Han Song

Han joined Juvena Therapeutics as a Research Associate to contribute to Dr. Li’s research on protein expression, purification pipelines, and to improve Juvena Therapeutics’ pipeline library of rejuvenating proteins for therapeutic purposes.

Han obtained his bachelor’s degree in biochemistry from the University of San Diego, with research areas focusing on exploring the enzymatic interactions of malate dehydrogenases and the utilization of defect-formations in the synthesis of metal-organic frameworks.

Before joining Juvena, Han worked as a Scientist III at the startup NovoNutrients for 4 years. He was heavily involved with the upstream and downstream process of gas fermentation using proprietary bioreactors and consortias. In addition to the fermentation work, he developed a novel synthetic biology platform to express high-value biomolecules ranging from enzymes, pharmaceuticals, to carotenoids in various consortia species. Later on, he took on the role of a strain engineer to develop a quick and reliable method to generate genomically-integrated strains of bacteria for industrial processes.

In Han’s free time, he enjoys playing the piano, hiking, and cycling around the Bay Area.

Learn more about Han

Back to Careers

Jamie Romero

Jamie Romero has over 14 years of biotech industry experience, starting as a Research Associate and growing into a Biotech Operations Manager. She brings to Juvena years of experience within the biotech industry, from her earlier days of working at the bench to managing biotech operations in scaling companies. Jamie has significant experience across facilities operations, office management, HR, accounting, and more. Jamie Romero’s career has fed her need to learn through the field of biomedical research while experiencing the excitement of the biotech start-up world. Jamie earned her Bachelors of Science in molecular biology and minor in Chemistry from SJSU.

Jamie is detail oriented, an effective multi-tasker and used to fast-paced, changing and uncertain environments. Having the ability to prioritize in deadline driven environments, Jamie excels when challenged, wearing multiple hats. She learned by dedicating 12 years to Omniox, Inc., where she was the first employee and grew with the company, taking on multiple diverse tasks to support their growth and needs, followed by Catalyst Biosciences. Many exciting opportunities opened up for her as she had the great opportunity to grow and learn in many different roles, being the “go-to” person; point-of-contact for, if, and, when anything came up through most if not all departments of the company – from lab to office, from finance to HR, from coordinating team-building and company events to providing EA support for the CEO and Executive team.

So, when Jamie came across the opportunity to join Juvena, an early, scaling biopharma start-up tackling some of the greatest unmet needs of our time through an exciting biologics discovery and development platform, a mission Jamie whole-heartedly believes in, she excitedly jumped to the challenge and can’t wait to see what the future with the company entails.

Learn more about Jamie

Back to Careers

Matthew Fust, MBA

Matthew is an advisor to life sciences companies, executive teams and investors. From 2009 through 2013, he was CFO of Onyx Pharmaceuticals, culminating in the company’s acquisition by Amgen. He previously served as CFO of Jazz Pharmaceuticals (2003 – 2008), CFO of Perlegen Sciences (2002 – 2003), and CFO of ALZA Corporation, where he was an executive from 1996 through the company’s acquisition by Johnson & Johnson in 2001. Prior to joining ALZA, Matthew was a member of the healthcare strategy consulting practice at Andersen Consulting (now Accenture).

He serves on the boards of directors of Atara Biotherapeutics, Crinetics Pharmaceuticals and Ultragenyx Pharmaceuticals. He is also an advisor to Out Leadership/Quorum and Women In Bio.

Matthew holds an undergraduate degree from the University of Minnesota and an M.B.A. from the Stanford University Graduate School of Business.

Learn more about Matthew

Back to Careers

Ameet Mallik, MBA

Ameet Mallik is CEO of ADC Therapeutics, and a member of the Board of Directors of Atara Biotherapeutics. Prior to that, Mr. Mallik served as Executive Vice President and Head, U.S. Oncology of Novartis. In this role, Mr. Mallik was responsible for Novartis’ commercial and medical oncology operations in the United States. Mr. Mallik also served as Global Head, Marketing, Value and Access, and as Head, Latin America and Canada, both for Novartis Oncology. Mr. Mallik began his career at Novartis as Head of Strategic Planning and has held a number of commercial leadership roles at Novartis and Sandoz. At Sandoz, Mr. Mallik was Global Head of Biopharmaceuticals & Oncology Injectables. Mr. Mallik previously worked as an Associate Principal at McKinsey and Company. Mr. Mallik holds an M.B.A. from The Wharton School at the University of Pennsylvania, and an M.S. in Biotechnology and B.S. in Chemical Engineering, both from Northwestern University.

Learn more about Ameet

Back to Careers

Nicholas E. Johnson, MD, MSCI, FAAN

Nicholas E. Johnson, MD, MSCI, FAAN is an associate professor, division chief of neuromuscular, and vice chair of research in the department of neurology at Virginia Commonwealth University with a focus in inherited neuromuscular disorders. He received his undergraduate degree in molecular and cellular biology and psychology at the University of Arizona. He then obtained his medical degree at the University of Arizona. He completed his neurology residency and combined fellowship in neuromuscular medicine and experimental therapeutics at the University of Rochester. His laboratory is focused on identifying the pathogenesis of myotonic dystrophy, the limb girdle muscular dystrophies, and facioscapulohumeral muscular dystrophy and identifying appropriate clinical endpoints for these conditions. Johnson conducts therapeutic trials in many other inherited nerve and muscle disorders.

Research Expertise

Translational laboratory focused on identifying genetic modifiers across muscular dystrophies, and developing clinical endpoints and patient reported outcomes for myotonic dystrophy, facioscapulohumeral muscular dystrophy, and the limb girdle muscular dystrophy. The laboratory uses cellular models to identify changes in RNA splicing in myotonic dystrophy.

Learn more about Dr. Johnson

LinkedIn
VCU

Back to Careers

Mike Nohaile, PhD

Mike Nohaile, PhD, is Chief Executive Officer at Prellis Biologics and former Senior Vice President of Strategy, Commercialization & Innovation at Amgen Inc. Dr. Nohaile joined Amgen as Vice President of Strategy in December 2012. Prior to Amgen, he served as the Head and General Manager of the Molecular Diagnostics Business Unit at Novartis. He served Novartis as the Head of Corporate Strategy and Head of Pharmaceutical Strategy.

Mike began his career at McKinsey & Company, as partner in the New Jersey office, where he worked extensively in the healthcare area with a particular focus on diagnostics, devices and pharmaceuticals. He has a doctorate in molecular and cell biology from University of California, Berkeley and he was a postdoctoral fellow at MIT in the Department of Biology.

Learn more about Mike

Back to Careers

Peter Jackson, PhD

Peter Jackson is a Professor in the Baxter Laboratory for Stem Cell Biology, Department of Microbiology & Immunology, at the Stanford University School of Medicine. Dr. Jackson returned to Stanford in 2013 after eight years as a Staff Scientist and Director at Genentech Inc. in S. San Francisco, California. At Genentech, he helped define and implement the development of therapeutics for cancer pathways including cell cycle checkpoints, stress pathways, and tumor metabolism. Before joining Genentech in 2005, he spent 10 years on the faculty at Stanford University School of Medicine. His laboratory has been involved in studies of cell cycle biochemistry, regulation of the cancer by kinases and phosphatases, the ubiquitin-proteasome system, and the discovery of a new physiological class of competitive (“pseudosubstrate”) E3 ubiquitin ligase inhibitors, exemplified by the APC/C regulator Emi1.

Since 2005, his lab has focused on signaling through the primary cilium, using proteomic approaches to define regulatory networks and new disease genes. More broadly, the lab has connected many proteins defective in human diseases and cancer to new complexes and pathways, with a view to discovering molecular signatures for diagnostics and therapeutic development. His research has earned him numerous visiting lectureships and honors, including awards from the Baxter Foundation, Howard Hughes Medical Institute, the American Cancer Society, the Pluto Society, and being a Stanford Hume Faculty Scholar and a Kirsch Scholar, and elected a Fellow of the American Association for the Advancement of Science (in 2008).

Learn more about Peter

LinkedIn
Stanford School of Medicine

Back to Careers

David Schaffer, PhD

David Schaffer is a Professor of Chemical and Biomolecular Engineering, Bioengineering, and Neuroscience at UC Berkeley, where he also serves as the Director of the Berkeley Stem Cell Center. In addition, he is Co-Founder, Acting CSO, and Co-Chairman of 4D Molecular Therapeutics.

At UC Berkeley, Dr. Schaffer applies engineering principles to enhance stem cell and gene therapy approaches for neuroregeneration, work that includes novel approaches for molecular engineering and evolution of new viral vectors as well as new technologies to investigate and control stem cell fate decisions.

Professor Schaffer served as Dr. Yousef’s co-thesis advisor (2008-2013).

Learn more about David

LinkedIn
UC Berkeley

Back to Careers

Irina Conboy, PhD

Irina Conboy is a Professor at the University of California, Berkeley in the Department of Bioengineering. Her discovery of the rejuvenating effects of young blood through parabiosis in a seminal paper published in Nature in 2005 paved the way for a thriving field of rejuvenation biology. The Conboy lab currently focuses on broad rejuvenation of tissue maintenance and repair, stem cell niche engineering, elucidating the mechanisms underlying muscle stem cell aging, directed organogenesis, and making CRISPR a therapeutic reality.

Professor Conboy served as Dr. Yousef’s co-thesis advisor (2008-2013).

Learn more about Irina

CONBOY LABORATORY
UC Berkeley

Back to Careers

Joe Wu, MD, PhD

Joseph C. Wu, MD, PhD, is Director of the Stanford Cardiovascular Institute and Simon H. Stertzer Endowed Professor in the Departments of Medicine (Cardiology) and Radiology at Stanford School of Medicine. Dr. Wu received his medical degree from Yale. He completed his medicine internship, residency, and cardiology fellowship (STAR program) at UCLA. He obtained his PhD in the Department of Molecular & Medical Pharmacology with Dr. Sam Sanjiv Gambhir. His clinical interests include adult congenital heart disease and cardiovascular imaging.

His lab works on biological mechanisms of patient-specific and disease-specific induced pluripotent stem cells (iPSCs) with a focus on cardiovascular disease mechanisms and the implementation of precision medicine for prevention and treatment of cardiovascular patients. His lab uses a combination of genomics, stem cells, cellular & molecular biology, physiological testing, and molecular imaging technologies. Dr. Wu has published >400 manuscripts with H-index of 101 on Google scholar and recognition as top 1% of highly cited researchers in Web of Science (2018, 2019 & 2020). Among his trainees, >30 of them are principal investigators in the US or abroad.

Dr. Wu has received numerous awards, including National Institutes of Health (NIH) Director’s New Innovator Award, NIH Roadmap Transformative Award, American Heart Association (AHA) Innovative Research Award, Presidential Early Career Award for Scientists and Engineers (PECASE) given out by President Obama, AHA Established Investigator Award, Burroughs Wellcome Foundation Innovation in Regulatory Science Award, AHA Merit Award, and AHA Distinguished Scientist Award. Dr. Wu serves on the Scientific Advisory Board for the Keystone Symposia, FDA Cellular, Tissue, and Gene Therapies Advisory Committee, AHA National Board of Directors, and Chair of the AHA National Research Committee.

Dr. Wu is an elected member of American Society of Clinical Investigators (ASCI), Association of University Cardiologists (AUC), American Institute for Medical and Biological Engineering (AIMBE), American Association of Physicians (AAP), American Association for the Advancement of Science (AAAS), and National Academy of Medicine (NAM).

In addition, he has been scientific co-founder of several startups.

Learn more about Joe

Stanford School of Medicine
LinkedIn

Han Song

Jamie Romero

Matthew Fust, MBA

Ameet Mallik, MBA

Nicholas E. Johnson, MD, MSCI, FAAN

Mike Nohaile, PhD

Peter Jackson, PhD

David Schaffer, PhD

Irina Conboy, PhD

Joe Wu, MD, PhD

Navigation

Contact

Stay in touch